Despite some cheering therapeutic successes, CAR-T cells, similar to endogenous T cells, demonstrate susceptible to inhibitory immune checkpoints present in the tumor microenvironment, such as the PD-1/PD-L1 axis (4). Here, CD274 is linked to neoplasm.